Anne Phelan
Direttore Tecnico/Scientifico/R&S presso BENEVOLENTAI
Posizioni attive di Anne Phelan
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| BENEVOLENTAI | Direttore Tecnico/Scientifico/R&S | 01/11/2019 | - |
BenevolentAI Cambridge Ltd.
 BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 03/01/2019 | - |
BenevolentAI Ltd.
 BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Direttore Tecnico/Scientifico/R&S | 01/09/2019 | - |
Storia della carriera di Anne Phelan
Precedenti posizioni note di Anne Phelan
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Direttore Tecnico/Scientifico/R&S | 01/01/2018 | 01/11/2018 |
| PFIZER, INC. | Corporate Officer/Principal | 01/04/2014 | 01/10/2015 |
Formazione di Anne Phelan
| University of Liverpool | Doctorate Degree |
Statistiche
Distribuzione geografica
| Regno Unito | 6 |
| Stati Uniti | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 4 |
| Commercial Services | 2 |
| Technology Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BENEVOLENTAI | Health Technology |
| PFIZER, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
BenevolentAI Cambridge Ltd.
BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Commercial Services |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Technology Services |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Anne Phelan
- Esperienza
